Glucose intolerance, diabetes or insulin resistance not linked with pathological features of AD

July 29, 2013

Glucose intolerance or insulin resistance do not appear to be associated with pathological features of Alzheimer disease (AD) or detection of the accumulation of the brain protein β-amyloid (Αβ), according to a report published by JAMA Neurology.

Glucose intolerance and diabetes mellitus have been proposed as risk factors for the development of AD, but evidence of this has not been consistent, the study background notes.

Madhav Thambisetty, M.D., Ph.D., of the National Institute on Aging, Baltimore, and colleagues investigated the association between glucose intolerance and and brain ?? burden with autopsies and imaging with carbon 11-labeled Pittsburgh Compound B tomography.

"The relationship among diabetes mellitus, insulin and AD is an important area of investigation. However, whether cognitive impairment seen in those with diabetes is mediated by excess pathological features of AD or other related abnormalities, such as vascular disease, remains unclear," the authors comment.

Two groups of participants were involved in the study. One group consisted of 197 participants enrolled in the Baltimore Longitudinal Study of Aging who had two or more oral glucose tolerance tests (OGTT) while they were alive and then underwent a brain autopsy when they died. The second group included 53 living who had two or more OGTTs and underwent imaging.

"In this prospective cohort with multiple assessments of and insulin resistance, measures of glucose and insulin homeostasis are not associated with AD pathology and likely play little role in AD pathogenesis," the study concludes. "Long-term therapeutic trials are important to elucidate this issue."

Explore further: Undiagnosed pre-diabetes highly prevalent in early Alzheimer's disease study

More information: JAMA Neurol. Published online July 29, 2013. doi:10.1001/jamaneurol.2013.284

Related Stories

Undiagnosed pre-diabetes highly prevalent in early Alzheimer's disease study

July 14, 2013
When Georgetown University neurologist R. Scott Turner, MD, PhD, began enrolling people with mild to moderate Alzheimer's disease into a nationwide study last year, he expected to find only a handful of participants with ...

Breakthrough research of essential molecule reveals important targets in diabetes and obesity

June 19, 2013
Insulin is the most potent physiological anabolic agent for tissue-building and energy storage, promoting the storage and synthesis of lipids, protein and carbohydrates, and inhibiting their breakdown and release into the ...

Sucralose affects response to oral glucose load in obese

July 2, 2013
(HealthDay)—For obese adults who do not use non-nutritive sweetener (NNS), sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in Diabetes Care.

Telmisartan reverses insulin resistance in mice

January 3, 2013
(HealthDay)—Treating mice fed a high-fat diet with telmisartan reverses insulin resistance and glucose intolerance, but only when the peroxisome proliferator-activated receptor-δ (PPAR-δ) gene is present, according to ...

Treatment of sleep apnea improves glucose levels in prediabetes

May 20, 2013
Optimal treatment of sleep apnea in patients with prediabetes improves blood sugar (glucose) levels and thus can reduce cardiometabolic risk, according to a study to be presented at the ATS 2013 International Conference in ...

Will green tea help you lose weight?

April 29, 2013
Evidence has shown that green tea extract may be an effective herbal remedy useful for weight control and helping to regulate glucose in type 2 diabetes. In order to ascertain whether green tea truly has this potential, Jae-Hyung ...

Recommended for you

Contact in sports may lead to differences in the brains of young, healthy athletes

August 22, 2017
People who play contact sports show changes to their brain structure and function, with sports that have greater risk of body contact showing greater effects on the brain, a new study has found.

Research reveals 'exquisite selectivity' of neuronal wiring in the cerebral cortex

August 21, 2017
The brain's astonishing anatomical complexity has been appreciated for over 100 years, when pioneers first trained microscopes on the profusion of branching structures that connect individual neurons. Even in the tiniest ...

Afternoon slump in reward response

August 21, 2017
Activation of a reward-processing brain region peaks in the morning and evening and dips at 2 p.m., finds a study of healthy young men published in The Journal of Neuroscience. This finding may parallel the drop in alertness ...

Researchers find monkey brain structure that decides if viewed objects are new or unidentified

August 18, 2017
A team of researchers working at the University of Tokyo School of Medicine has found what they believe is the part of the monkey brain that decides if something that is being viewed is recognizable. In their paper published ...

Artificial neural networks decode brain activity during performed and imagined movements

August 18, 2017
Artificial intelligence has far outpaced human intelligence in certain tasks. Several groups from the Freiburg excellence cluster BrainLinks-BrainTools led by neuroscientist private lecturer Dr. Tonio Ball are showing how ...

Study of nervous system cells can help to understand degenerative diseases

August 18, 2017
The results of a new study show that many of the genes expressed by microglia differ between humans and mice, which are frequently used as animal models in research on Alzheimer's disease and other neurodegenerative disorders.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gaucho25
not rated yet Jul 29, 2013
A new FDA approved diet pill called Belviq just went on the market. Belviq make people more likely to succeed with weight loss since they feel full more quickly and it reduces food cravings. People who take Belviq with diet and exercise were 2 times more likely to lose 5% body weight and 3 times more likely to lose 10% body weight than the people who just did diet and exercise alone. The label states that if you do not lose 5% of your body weight in 12 weeks then consider stopping. Those that do respond in 12 (about 45% of patients) weeks go on to lose over 10% of their body weight in one year. Losing 22 pounds for a 220 pound person is life changing. So 45% of those taking Belviq lose significant amount of weight.
Belviq has a second mode of action to reduce blood sugar which may end up preventing diabetes in many cases. Diabetics and pre-diabetics who took Belviq, REGARDLESS of weight loss, saw their blood sugar numbers drop by double digit percentages. IE HbA1c -0.9 to -1.2 and fasting glucose feel -27. The cost of medications to reduce HbA1c levels exceeds the cost of Belviq. (seeArena's BloomDM phase III trial) These reductions in diabetic symptoms plus the weight loss at the same time makes Belviq a medical bargain.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.